HUE027050T2 - Treatment of glomerulonephritis - Google Patents

Treatment of glomerulonephritis Download PDF

Info

Publication number
HUE027050T2
HUE027050T2 HUE10722643A HUE10722643A HUE027050T2 HU E027050 T2 HUE027050 T2 HU E027050T2 HU E10722643 A HUE10722643 A HU E10722643A HU E10722643 A HUE10722643 A HU E10722643A HU E027050 T2 HUE027050 T2 HU E027050T2
Authority
HU
Hungary
Prior art keywords
compound
group
use according
glomerulonephritis
formula
Prior art date
Application number
HUE10722643A
Other languages
English (en)
Hungarian (hu)
Inventor
Berit Johansen
Andrea Huwiler
Original Assignee
Avexxin As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin As filed Critical Avexxin As
Publication of HUE027050T2 publication Critical patent/HUE027050T2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HUE10722643A 2009-06-04 2010-06-04 Treatment of glomerulonephritis HUE027050T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0909643A GB0909643D0 (en) 2009-06-04 2009-06-04 Glomerulonephritis treatment

Publications (1)

Publication Number Publication Date
HUE027050T2 true HUE027050T2 (en) 2016-08-29

Family

ID=40936918

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE10722643A HUE027050T2 (en) 2009-06-04 2010-06-04 Treatment of glomerulonephritis
HUE14158421A HUE030085T2 (en) 2009-06-04 2010-06-04 Treatment of glomerulonephritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE14158421A HUE030085T2 (en) 2009-06-04 2010-06-04 Treatment of glomerulonephritis

Country Status (14)

Country Link
US (3) US20120136066A1 (enExample)
EP (2) EP2437739B1 (enExample)
JP (1) JP5837481B2 (enExample)
AU (1) AU2010256013B2 (enExample)
CA (1) CA2764465C (enExample)
CY (1) CY1118269T1 (enExample)
DK (2) DK2437739T3 (enExample)
ES (2) ES2546198T3 (enExample)
GB (1) GB0909643D0 (enExample)
HU (2) HUE027050T2 (enExample)
LT (1) LT2745837T (enExample)
PL (2) PL2745837T3 (enExample)
PT (2) PT2745837T (enExample)
WO (1) WO2010139482A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014633D0 (en) * 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) * 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
WO2018055062A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
US20220257531A1 (en) * 2017-06-16 2022-08-18 Avexxin As Compositions and methods for treatment of a fibrotic disease
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼa2阻害剤
CA2251780A1 (en) * 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fatty acids
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
AU4994899A (en) 1998-07-13 2000-02-01 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
US6031014A (en) * 1998-12-08 2000-02-29 Crivello; James V. Initiator compositions and methods for their synthesis and use
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
RU2356247C2 (ru) * 2003-03-18 2009-05-27 Новартис Аг Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор
NZ552238A (en) * 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
US20100144827A1 (en) 2006-12-20 2010-06-10 Medwell Laboratories Ltd. C/O Ngt Technological Incubator Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
WO2009061208A1 (en) * 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament

Also Published As

Publication number Publication date
AU2010256013A1 (en) 2012-01-12
EP2745837A1 (en) 2014-06-25
EP2437739A1 (en) 2012-04-11
WO2010139482A1 (en) 2010-12-09
US20120136066A1 (en) 2012-05-31
ES2546198T3 (es) 2015-09-21
PL2745837T3 (pl) 2017-01-31
DK2745837T3 (en) 2016-08-29
AU2010256013B2 (en) 2013-05-16
JP2012528813A (ja) 2012-11-15
US20140256824A1 (en) 2014-09-11
LT2745837T (lt) 2016-10-25
CY1118269T1 (el) 2017-06-28
GB0909643D0 (en) 2009-07-22
EP2745837B1 (en) 2016-07-27
DK2437739T3 (en) 2015-08-17
US8796251B2 (en) 2014-08-05
HUE030085T2 (en) 2017-04-28
US20100311843A1 (en) 2010-12-09
ES2587719T3 (es) 2016-10-26
CA2764465C (en) 2018-03-20
CA2764465A1 (en) 2010-12-09
JP5837481B2 (ja) 2015-12-24
PT2437739E (pt) 2015-10-12
EP2437739B1 (en) 2015-07-29
PT2745837T (pt) 2016-08-22
PL2437739T3 (pl) 2015-11-30
US9187396B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
HUE027050T2 (en) Treatment of glomerulonephritis
AU2011298340B2 (en) Rheumatoid arthritis treatment using polyunsaturated long chain ketones
JP2023014350A (ja) 心臓代謝の効率を高めるための組成物および方法
JP4427825B2 (ja) コレステロール低下作用を有する医薬組成物
JP2013522217A (ja) α−トコフェロールキノン誘導体の合成およびその使用方法
WO2014082960A1 (en) Dermatitis treatment
CA1330446C (en) Phenolic thioalkylamides as inhibitors of 5-lipoxygenase
JP2000034230A (ja) 含硫黄抗真菌剤
CN109476611B (zh) 一种卤代化合物及其轴手性异构体
DE2456958A1 (de) 3-(p-biphenylyl)-butyronitril und seine anwendung als arzneimittel
CN117242076A (zh) 基于噻吩的化合物及其作为bckdk抑制剂的用途
CN110204493B (zh) 三环类xor抑制剂及其制备方法和应用
JPH0640990A (ja) 新規化合物
AT396469B (de) Verfahren zur herstellung neuer brenzcatechinderivate
WO2021104507A1 (zh) 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
WO2015064447A1 (ja) フラタキシン増強剤
EP0098204A1 (fr) Compositions thérapeutiques à base d'hydrazones N-substituées et nouvelles hydrazones N-substituées
JP3857428B2 (ja) 抗真菌剤
Wang et al. Discovery and Optimization of Ester-linked Ibuprofen-Glycine Hybrids as the NF-κB Pathway Inhibitors for the Treatment of ulcerative colitis
WO2019159868A1 (ja) 大腸炎改善剤
JP2023514236A (ja) ピラジン化合物およびその調製方法と使用
CN114315689A (zh) 二硫烷基邻苯二甲酰亚胺类化合物、其制备方法和用途
JP2000034285A (ja) 抗真菌剤